Blog

BioSpace: Harnessing Nature for Faster mRNA Vaccine Manufacturing

November 25, 2020

GreenLight CEO, Andrey Zarur, speaks to Biospace about the potential of a messenger RNA vaccine for Covid-19

messenger RNA vaccine explaine dby Andrey Zarur
Andrey Zarur, Ph.D., president and CEO of GreenLight Biosciences.

With manufacturing capacity in the news following the announcement of successful Covid-19 vaccine trials, Greenlight Biosciences CEO Andrey Zarur explains to Biospace the potential of the messenger RNA vaccine:

“The silver lining in the pandemic is that it occurred at a time when companies like BioNTech, Pfizer and Moderna had been developing messenger RNA. It’s the only reason we can respond as quickly as we are.

“Unfortunately, the industry isn’t ready to manufacture messenger RNA at large scale….[the] method… is limited by the ability to source enough raw materials – the nucleotides and enzymes – from those who manufacture them at scale.”

“We make all the components necessary for mRNA…We believe our method is the fastest way to harness nature and mimic it.”

“We hope to be in the facility by the second quarter of 2021… Our goal is not to compete against companies, but against the virus…The best thing we can do right now is get our manufacturing facility up and running. We’re here to help.”


More of Greenlight Biosciences in the news: